<SEC-DOCUMENT>0001493152-23-009464.txt : 20230329
<SEC-HEADER>0001493152-23-009464.hdr.sgml : 20230329
<ACCEPTANCE-DATETIME>20230329160548
ACCESSION NUMBER:		0001493152-23-009464
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20230329
DATE AS OF CHANGE:		20230329

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABEONA THERAPEUTICS INC.
		CENTRAL INDEX KEY:			0000318306
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				830221517
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-256850
		FILM NUMBER:		23775229

	BUSINESS ADDRESS:	
		STREET 1:		1330 AVENUE OF THE AMERICAS, 33RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
		BUSINESS PHONE:		646-813-4701

	MAIL ADDRESS:	
		STREET 1:		1330 AVENUE OF THE AMERICAS, 33RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PLASMATECH BIOPHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20140922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ACCESS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19960209

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHEMEX PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>form424b5.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed
Pursuant to Rule 424(b)(5)<BR>
Registration No. 333-256850</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS
SUPPLEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(To
Prospectus dated October 22, 2021, as supplemented by Prospectus Supplement No. 1 dated November 19, 2021, Prospectus Supplement No.
2 dated July 19, 2022 and Prospectus Supplement No. 3 dated October 12, 2022)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="logo_001.jpg" ALT="" STYLE="height: 49.5pt; width: 156pt"></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Up
to $4,872,300</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement amends and supplements the information in the prospectus, dated October 22, 2021 (the &ldquo;Prospectus&rdquo;),
filed with the Securities and Exchange Commission as a part of our registration statement on Form S-3 (File No. 333-256850), as previously
supplemented by Prospectus Supplement No. 1 dated November 19, 2021, Prospectus Supplement No. 2 dated July 19, 2022 and Prospectus Supplement
No. 3 dated October 12, 2022, relating to the offer and sale of up to $150,000,000 of shares of our common stock, pursuant to the Open
Market Sale Agreement<SUP>SM</SUP>, as amended (the &ldquo;Sale Agreement&rdquo;), we previously entered into with Jefferies LLC (&ldquo;Jefferies&rdquo;).
This prospectus supplement should be read in conjunction with the Prospectus, and is qualified by reference thereto, except to the extent
that the information herein amends or supersedes the information contained in the Prospectus. This prospectus supplement is not complete
without, and may only be delivered or utilized in connection with, the Prospectus and any future amendments or supplements thereto. Through
March 29, 2023, we have sold 10,237,760 shares of our common stock for aggregate gross proceeds of approximately $39.1 million in accordance
with the Sale Agreement under the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are filing this prospectus supplement to amend the Prospectus because we are subject to General Instruction I.B.6. of Form S-3, which
limits the amounts that we may sell under the registration statement of which this prospectus supplement and the Prospectus are a part.
After giving effect to these limitations and the current public float of our common stock, and after giving effect to the terms of the
Sale Agreement, we currently may offer and sell shares of our common stock having an aggregate offering price of up to $4,872,300 under
the Sale Agreement. If our public float increases such that we may sell additional amounts under the Sale Agreement and the registration
statement of which this prospectus supplement and the Prospectus are a part, we will file another prospectus supplement prior to making
additional sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on the Nasdaq Capital Market under the symbol &ldquo;ABEO.&rdquo; The aggregate market value of our common stock
held by non-affiliates as of March 29, 2023 pursuant to General Instruction I.B.6 of Form S-3 is $54,546,886, which was calculated based
on 16,681,005 shares of our common stock outstanding held by non-affiliates and at a price of $3.27 per share, the closing price of our
common stock on March 8, 2023. As of the date hereof, we have sold an aggregate of $13,309,995 of securities pursuant to General Instruction
I.B.6 of Form S-3 during the prior 12 calendar month period that ends on and includes the date hereof. As a result of the limitations
of General Instruction I.B.6 of Form S-3, and in accordance with the terms of the Sales Agreement, we are registering the offer and sale
of shares of our common stock having an aggregate offering price up to $4,872,300 from time to time through Jefferies. In addition, we
have agreed to reimburse the Agent for fees and disbursements paid to its legal counsel, in an amount not to exceed $50,000, in connection
with this prospectus supplement and, upon the occurrence of certain events specified in the Sale Agreement, up to $15,000 in connection
with each such specified event. In accordance with FINRA Rule 5110, these reimbursed fees and expenses are deemed sales compensation
for this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investing
in our securities involves significant risks. Please see &ldquo;Risk Factors&rdquo; beginning on page S-4 of the Prospectus and in the
documents incorporated by reference into the Prospectus and in our most recent Annual Report on Form 10-K and in our most recent Quarterly
Reports on Form 10-Q, and any amendments thereto, which are incorporated by reference into the Prospectus, and under similar headings
in the other documents that are filed after the date hereof and incorporated by reference into this prospectus supplement and the Prospectus
for a discussion of the factors you should carefully consider before deciding to purchase our common stock.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
upon the adequacy or accuracy of the Prospectus, this prospectus supplement or the accompanying prospectus. Any representation to the
contrary is a criminal offense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jefferies
LLC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
date of this prospectus supplement is March 29, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo_001.jpg
<TEXT>
begin 644 logo_001.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M[&2VE^Z^V5-BLC_W*];_ &P-?U)?#OA#PCI.H3:5/XMUZWTJ:\MWVNENV?-
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MN:M:+H,^G^(/$%](\;1:A/%+&J#YEVPJGS?]\UCZ+IOB'P_:W%E:V.GWUO\
M:9YX99KYXG*RRO)\P\IN?GI2E(4G,Z9?$&G_ -@_VU]HB_LSR/M7VC/R>5MW
M;_RK%L_B#I-Q=6UNXOK:6Z/EP_;-/G@5V_N[F0+NXJS=:/?ZEX)FTZ[2QGU*
M6T\J0-&WV5I-O]W[VW-<U:^$=>74M.EB4:7#%,DER_\ ;EU>;HE^]%Y4J!?F
M_O=>*<I2(ES^[RGI]%%%:G6)ZU!112ZD/=$M)ZT44I;#ZHDHHHIK8H****8!
C2444@%HHHI@%%%% !1110 4444 %%%% !2444 +1110!_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
